v3.26.1
Collaborative and Other Relationships - Prelude (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Nov. 30, 2025
Jun. 30, 2026
Dec. 31, 2025
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
License Agreements            
Research and development   $ 516,950   $ 494,917 $ 1,032,853 $ 932,196
Long term equity investments   104,387 $ 47,991 [1]   104,387  
Investment in Prelude            
License Agreements            
Payments to acquire equity securities $ 25,000          
Investment owned (in shares) 6,250,000          
Per share price (in USD per share) $ 4.00          
Long term equity investments $ 7,900 33,300 18,100   33,300  
Unrealized gain on equity investments   $ 11,900     $ 15,200  
Prelude            
License Agreements            
Payment to acquire license agreement 60,000          
Upfront payment under license agreement 35,000          
Research and development     $ 17,100      
Milestone payment made under license agreement 100,000          
Prelude | Clinical And Regulatory Milestones And Single Digit Royalties On Global Net Sales | Maximum            
License Agreements            
Additional milestone payments under the license agreement $ 775,000          
[1] The condensed consolidated balance sheet at December 31, 2025 has been derived from the audited consolidated financial statements at that date.